Alternative medical treatment for endometriosis

H Taylor, M Guarnaccia, D Olive
Seminars in reproductive endocrinology · 1997 · doi:10.1055/s-2008-1068758 · PMID:9383837
review OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

This paper reviews new medical therapies for endometriosis and discusses their evaluation, noting that some alternative treatments have proven benefit while others show promise.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-11 · read from full text ⓘ

The paper is a narrative review chapter describing alternative medical therapies for endometriosis beyond the limited set of drugs commonly used as standard treatment. It outlines that some alternative medications have been rigorously evaluated and shown benefit, whereas others have only preliminary evidence from early trials or animal models, emphasizing the importance of proper study design and outcome evaluation when assessing medical therapies. A stated limitation is that the evidence base for some alternatives is not yet definitive, relying on preliminary results or preclinical models. This paper is centrally about endometriosis — it reviews and discusses the evaluation of alternative medical treatments for endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Although a limited number of drugs make up the mainstay of treatment of endometriosis, many alternative medications have been used in an attempt to improve efficacy. Some have been rigorously evaluated and are of proven benefit, while others show promise in preliminary trials or in animal models. Proper methods of evaluating medical therapy and outcomes are essential. This chapter provides a review of new medical therapies for the treatment of endometriosis and their evaluation.
Full text 924 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Although a limited number of drugs make up the mainstay of treatment of endometriosis, many alternative medications have been used in an attempt to improve efficacy. Some have been rigorously evaluated and are of proven benefit, while others show promise in preliminary trials or in animal models. Proper methods of evaluating medical therapy and outcomes are essential. This chapter provides a review of new medical therapies for the treatment of endometriosis and their evaluation.

Keywords

Endometriosis - progestogens - gestrinone - mifepristone

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Complementary Therapies Endometriosis Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Endometriosis Female Gestrinone Gestrinone Humans Mifepristone Mifepristone Progesterone Congeners Progesterone Congeners Progestins Progestins

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-20T06:14:18.781669+00:00
pubmed
last seen: 2026-05-13T22:10:52.568893+00:00
unpaywall
last seen: 2026-06-20T06:35:16.286784+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine